LYPLA2 and colitis: Animal experiments show that the knockdown of Zdhhc7 or inhibition of APT2 to interrupt the palmitoylation-depalmitoylation cycle alleviates the symptoms of colitis in a mouse model, suggesting that the STAT3 palmitoylation cycle and its regulatory enzymes may be new therapeutic targets for colitis (142).